MetaCap

Anixa Biosciences (ANIX) vs Organigram Global (OGI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Anixa Biosciences (ANIX) has outperformed Organigram Global (OGI) over the past year, losing 43.8% versus a loss of 60.6%. Over five years, ANIX leads with a -38.7% price change compared with -93.3% for OGI. Anixa Biosciences is the larger company by market cap ($84.8 million vs $82.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIX-43.78%OGI-60.61%
+48%-9%-66%
Nov 21, 20251 yearNov 20, 2026
ANIX-40.92%OGI-92.71%
+51%-24%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIX versus OGI key metrics
MetricANIXOGI
Share price$2.44$0.583
Market cap$84.82M$82.27M
1-day change-6.15%-7.40%
YTD return-21.79%-65.30%
1-year return-43.78%-60.61%
5-year return-38.69%-93.25%
P/E ratio (TTM)—1.36
Forward P/E—27.76
EPS (TTM)$-0.32$0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-10.93M—
52-week high$5.46$2.24
52-week low$2.32$0.583
Distance from 52-week high-55.31%-73.97%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+296.31%—
Average volume282.29K567.77K
Shares outstanding34.76M141.11M
Employees41,139
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANIX has outperformed OGI by 16.8 percentage points over the past year.

About Anixa Biosciences

ANIX stock →

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Organigram Global

OGI stock →

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees

ANIX vs OGI FAQ

Which is bigger, Anixa Biosciences or Organigram Global?

Anixa Biosciences (ANIX) is larger, with a market capitalization of $84.82M compared with $82.27M for Organigram Global (OGI).

Which stock has performed better over the past year, ANIX or OGI?

ANIX returned -43.78% over the past 12 months, compared with -60.61% for OGI (price return, excluding dividends). Past performance does not predict future results.

Are Anixa Biosciences and Organigram Global in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons